Viemed Healthcare (VMD) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Viemed Healthcare

NasdaqCM•Healthcare•Medical Devices

$8.79+0.04(<0.01%)Pre-market

Market Cap

$336.18M

P/E

23.2x

P/S

1.1x

P/B

2.3x

Viemed Healthcare, Inc., through its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services in the United States. The company provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD. It also sells and rents HME devices, such as non-invasive and invasive ventilators, positive airway pressure (PAP) machines, durable medical equipment, percussion vests, oxygen concentrators, and other medical equipment. In addition, the company provides neuromuscular care and oxygen therapy services; and sleep apnea management which provides sleep solutions and/or equipment, such as PAP, automatic continuous positive airway pressure, and bi-level positive airway pressure machines. Further, it offers in-home sleep apnea testing services; and breast pumps and related lactation equipment and supplies, including fulfillment and support services, as well as healthcare staffing and recruitment services. Viemed Healthcare, Inc. was founded in 2006 and is headquartered in Lafayette, Louisiana.

How this company scores

GoodMetricSide Score: 77/100

Strongest: Cash & Earnings Quality (22/25); weakest: Profitability (14/25).

Profitability14/25

Growth21/25

Balance Sheet & Red Flags20/25

Cash & Earnings Quality22/25

Strengths

Growing revenueLow leverageInterest easily coveredCash-backed earnings

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 23.2x5y range 18.8x – 60.2x

Currently near its 20-quarter median.

P/S · 1.1x5y range 1.0x – 2.5x

Currently below its 20-quarter median.

P/B · 2.3x5y range 1.9x – 3.6x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

Some Concerns

Margin Pressure

Watch

Operating margins declined 13.4% — watch for continued compression, which may signal competitive or cost pressure.

Earnings Quality

Watch

FCF/Net Income has dropped below 0.7x in 3 quarters — monitor for earnings quality deterioration.

Price & Volume

Market Cap $336.18M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $301.61M
Q. Revenue: $78.10M
TTM EBITDA: $24.33M
TTM Op. Income: $22.77M
Q. Op. Income: $4.46M
TTM Net Income: $14.50M
Q. Net Income: $2.76M
EPS: $0.07
Shares Out.: $38.25M

$301.61M in TTM revenue grew 25.2% YoY, reaching $78.10M last quarter. TTM EBITDA of $24.33M and TTM operating income of $22.77M show growth is flowing through to the bottom line. TTM net income of $14.50M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 7 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 57.7%
EBITDA Margin: 6.2%
Op. Margin: 5.7%
Net Margin: 3.5%

Op. margin of 5.7% is down 2.4% YoY — costs are rising relative to revenue. Net margin at 3.5% and gross margin of 57.7% show how much of each revenue dollar survives to profit. Over the past year, operating margin is down 29% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 23.2x
P/S Ratio: 1.1x
P/B Ratio: 2.3x

At 23.2x P/E, the stock trades within typical market levels. P/S of 1.1x and P/B of 2.3x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Over the past year, P/E is up 19% — an improving trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $204.22M
Cash: $10.68M
Long-Term Debt: $6.37M
Book Value: $144.03M
D/E Ratio: 0.0
Debt/EBITDA: 1.3

With $204.22M in assets and $6.37M in long-term debt, D/E is 0.0and book value is $144.03M — a conservative capital structure with a cushion to weather downturns. Across the last 8 quarters, debt/equity has fallen for 3 consecutive quarters — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $15.90M
TTM Free Cash Flow: $29.24M
FCF Margin: 9.7%
FCF / Net Income: 2.0

TTM FCF of $29.24M on $15.90M in operating cash flow. The FCF / Net Income ratio of 2.0x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has risen for 5 consecutive quarters — an improving trend.